Sindrom Asperger

01Pathophysiology

Asperger's Syndrome is a neurodevelopmental disorder that belongs to the pervasive developmental disorder (gangguan perkembangan pervasif) group in PPDGJ-III. The core abnormality lies in the neural circuits governing social cognition and behavioral flexibility, without the global developmental delay seen in childhood autism.

The prefrontal cortex, which mediates executive function, theory of mind, and behavioral planning, shows functional differences in affected individuals. This explains the difficulty in understanding other people's perspectives, reading social cues, and adapting behavior to changing social contexts. Patients can speak fluently and may even have advanced vocabularies, yet they fail to use language in a socially reciprocal way because the pragmatic (social-use) layer of language is impaired while the structural (grammar, vocabulary) layer is preserved.

The amygdala, responsible for processing emotional salience and facial expressions, is implicated in the poor recognition of nonverbal communication. This is why patients characteristically avoid eye contact or fail to modulate their tone of voice, and why they struggle to interpret sarcasm, irony, or implied meaning.

Mirror neuron dysfunction has been proposed as a contributor to the lack of intuitive social imitation and empathy. Patients do not lack the desire for social connection; they lack the automatic neural machinery to execute it smoothly. This distinction is important because it separates Asperger's from conditions like antisocial personality disorder, where social disengagement is volitional.

The restricted, repetitive interests are thought to arise from altered reward circuitry in the basal ganglia and orbitofrontal cortex, leading to an exaggerated drive for sameness and narrow but intense engagement with circumscribed topics. These are not obsessions in the OCD sense (they are ego-syntonic and pleasurable), which is a frequently tested distinction.

02Classification and Clinical Manifestation

Diagnostic Criteria per PPDGJ-III

Clinical Manifestation by Domain

03Diagnostic Workup

The diagnosis of Asperger's Syndrome under PPDGJ-III is entirely clinical. There is no blood test, imaging study, or biomarker that confirms it.

The best initial step is always a thorough developmental history taken from caregivers. The examiner must establish two things simultaneously: (1) that language and cognitive milestones were reached on time, and (2) that qualitative social deficits and restricted interests are present. The history should probe for first words, phrase speech timing, early social behaviors (pointing, joint attention, pretend play), and the onset and nature of narrow interests.

The most accurate diagnostic tool in clinical practice is the ADOS-2 (Autism Diagnostic Observation Schedule, 2nd Edition), a standardized, semi-structured interaction that allows the clinician to directly observe social communication behaviors and repetitive patterns. It is the closest equivalent to a "gold standard" for pervasive developmental disorders.

The ADI-R complements the ADOS-2 by providing structured retrospective data from caregivers. Together, these two instruments form the backbone of a rigorous diagnostic evaluation.

IQ testing is essential not to diagnose Asperger's itself but to exclude intellectual disability and to characterize the cognitive profile. A classic finding is a discrepancy between relatively stronger verbal IQ and weaker performance IQ, though this is not universal.

Neuroimaging and genetic testing are not part of the routine workup. They are reserved for atypical presentations, such as regression of skills, seizures, dysmorphic features, or microcephaly, where a secondary or syndromic etiology must be excluded.

04Management and Treatment

There is no cure for Asperger's Syndrome, and pharmacotherapy does not target the core features of the disorder. The first-line treatment is always psychosocial and educational intervention.

Social skills training is the single most important intervention and should be recommended for essentially all patients. Group-based formats are preferred because they allow real-time practice with peers under clinician guidance. Programs such as PEERS (Program for the Education and Enrichment of Relational Skills) have the strongest evidence base for adolescents and young adults.

CBT is the treatment of choice for the anxiety and emotional dysregulation that accompany the disorder in the majority of patients. Standard CBT protocols require modification: sessions should use visual schedules, concrete examples, and written social stories rather than abstract discussion.

Pharmacotherapy enters the picture only for comorbid conditions. The two FDA-approved medications for irritability associated with autism spectrum disorder are risperidone (approved for ages 5-16) and aripiprazole (approved for ages 6-17). These are used for severe behavioral disturbance, not for social deficits. Metabolic monitoring (weight, fasting glucose, lipid panel) is required at baseline and periodically during treatment due to the risk of weight gain and metabolic syndrome with risperidone.

SSRIs are first-line for comorbid anxiety or depressive disorders but should be started at lower doses than in neurotypical populations because patients with pervasive developmental disorders are more sensitive to activation side effects. Fluoxetine and sertraline have the most evidence.

Stimulants for comorbid ADHD symptoms are appropriate but require careful monitoring, as irritability is a more common side effect in this population than in children with ADHD alone.

A critical exam concept: the "next best step" in a newly diagnosed patient is always referral for psychosocial intervention and educational planning, not a prescription.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students lose points on this topic is by confusing Asperger's Syndrome with childhood autism. The PPDGJ-III makes the distinction entirely on the basis of language and cognitive development: if the child had normal milestones, it is Asperger's; if there was a clinically apparent delay, it is autism. Vignettes will test this by including a line such as "the child spoke his first words at 12 months and used two-word phrases by age 2" as the signal pointing you toward Asperger's and away from autism.

A second common trap involves the restricted interests. Test-writers will describe a child who talks incessantly about a single subject (e.g., electricity pylons, train schedules) and offer OCD as a distractor. The discriminator is the ego-syntonic versus ego-dystonic nature of the behavior. If the child enjoys the preoccupation and is not distressed by it, it is not OCD.

Third, beware of the "high-functioning autism" conflation. Under PPDGJ-III (and ICD-10), Asperger's Syndrome is a separate diagnostic entity from autism, not simply "mild autism." The key tested concept is that the distinction rests on developmental history, not on current severity of symptoms.

Finally, for management questions, remember that medication is never the first answer. The examinable principle is that psychosocial intervention and educational support are always the initial and primary treatment. Medication is adjunctive and targets comorbidities (anxiety, irritability, ADHD symptoms), not the core social or behavioral features of the disorder.